Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 16:11 ET | Source: Hagens Berman Sobol Shapiro LLP

QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
April 02, 2026 15:25 ET | Source: IGEL

IGEL Now & Next® 2026 Concludes in Miami with Breakthroughs in Secure Endpoints, Modern EUC, and Ecosystem Innovation

IGEL Now & Next® 2026 highlights innovations, integrations across IGEL’s platform, spanning endpoint security, workspace delivery, and partner expansion.
April 02, 2026 13:45 ET | Source: EverPass Media

EverPass Media Expands Relationship with Netflix; Secures Exclusive Commercial Rights to Distribute Upcoming Fury vs. Makhmudov Fight in the U.S.

The landmark fight will take place on Saturday, April 11 and will be available to stream via EverPass’ platform at bars, restaurants and hotels NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) --...
April 02, 2026 12:15 ET | Source: Optimove

Optimove Mid-Tournament March Madness 2026 Analysis: Betting Surges 60%, With 97% of Bettors Being Loyal Players on Online Sportsbook Platforms

New York, April 02, 2026 (GLOBE NEWSWIRE) -- Heading into March Madness 2026 final weekend, Optimove Insights has analyzed betting behavior across more than 3.1 million US sports bettors from...
April 02, 2026 11:45 ET | Source: Transgene S.A.

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
April 02, 2026 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
April 02, 2026 07:00 ET | Source: Adagene Inc.

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement...
April 01, 2026 18:22 ET | Source: CREDICORP LTD. C/O BANCO DE CREDITO

Credicorp Ltd.: Credicorp Announces Three New Directors, Reelection of Six Existing Directors, and New Committee Composition

Lima, April 01, 2026 (GLOBE NEWSWIRE) -- Lima, Peru – April 1, 2026 – Credicorp Ltd. (“Credicorp” or “the Company”) (NYSE: BAP), the leading financial services holding company in Peru with presence...
April 01, 2026 17:12 ET | Source: Beam Therapeutics

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31...
April 01, 2026 17:00 ET | Source: Adagene Inc.

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4...